13.9.2002
9.00-9.05	Seppo Ylä-Herttuala: Opening remarks
Session I	Chairman: Kari Alitalo
9.05-10.00	Inder Verma (La Jolla): Gene therapy. Facts and reality
10.00-10.30	Luigi Naldini (Torino): New lentiviral vectors
10.30-11.00	Coffee break
11.00-11.30	Carlos Lois (Boston): A lentiviral strategy to target the germline
11.30-12.00	Stefan Kochanek (Cologne): Helper-dependent high capacity adenoviruses
12.00-12.30	Olivier Danos (Paris): Gene and cell-based therapies for muscle and brain disorders
12.30-13.30	Lunch
13.30-14.00	Posters
Session II	Chairman: Seppo Ylä-Herttuala
14.00-14.50	Ronald Crystal (New York): Angiogenic gene therapy
14.50-15.20	Kari Alitalo (Helsinki): Lymphangiogenesis using viral vectors
15.20-15.50	Coffee break
15.50-16.20	Seppo Ylä-Herttuala (Kuopio): Gene therapy of peripheral vascular disease
16.20-16.50	Karin Joos: Anti-angiogenic gene therapy
16.50-17.20	C.I. Edvard Smith (Stockholm): The Bioplex technology: hybridizing functions to plasmids by peptide-nucleic acids
17.30-18.30	FGTS Annual Meeting
19.00-	Get together party at Biomedicum
14.9.2002
Session III	Chairman: Anu Jalanko
9.00-9.20	Akseli Hemminki (Birmingham): Adenoviral gene therapy for ovarian cancery
9.20-9.40	Katri Pajusola (Zürich): Targeting of AAV to the vascular wall
9.40-10.00	Kari Airenne (Kuopio): Baculovirus vectors
10.00-10.30	Coffee break Selected papers from the abstracts
10.30-10.45	Kenneth Lundström: Clinical and preclinical cancer therapy studies with liposome-encapsulated drugs and viruses
10.45-11.00	Mikko Savontaus: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells
11.00-11.15	Mikko Laukkanena: Linear amplificaation mediated PCR in retrovirus clonal tracking in rhesus monkey model
11.15-11.30	Tanja Hakkarainen: CD40 is expressed in ovarian cancer cells and can be utilized for targeting adenoviruses
11.30-11.45	Juha Rutanen: Gene transfer to myocardium
11.50-12.00	Seppo Ylä-Herttuala: Closing remarks
12.00-	Lunch